Allergy Therapeutics (AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short course subcutaneous allergy immunotherapy (AIT) platform, which continues to make strong market share gains in a competitive environment. Several products using the PQ platform are in late-stage development, with the aim of moving them to full registration under new regulatory frameworks in both the EU and the US. AGY has just announced a
16 Jan 2020
Sales growth well above market average
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sales growth well above market average
Allergy Therapeutics plc (AGY:LON) | 3.2 0 0.8% | Mkt Cap: 150.1m
- Published:
16 Jan 2020 -
Author:
Martin Hall -
Pages:
4
Allergy Therapeutics (AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short course subcutaneous allergy immunotherapy (AIT) platform, which continues to make strong market share gains in a competitive environment. Several products using the PQ platform are in late-stage development, with the aim of moving them to full registration under new regulatory frameworks in both the EU and the US. AGY has just announced a